Alcoholic and Non-Alcoholic Fatty Liver Disease

1. Front Matter

   Pages i-xvi

   PDF

2. Epidemiology and Risk Factors for Alcoholic Liver Disease

   • Mariana Lazo, Mack C. Mitchell

   Pages 1-20

3. Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease

   • Abhijit Chowdhury, Zobair M. Younossi

   Pages 21-40

4. Pathogenesis of Alcoholic Liver Disease

   • Gavin E. Arteel, David W. Crabb

   Pages 41-69

5. Pathogenesis of NAFLD and NASH

   • Jacquelyn J. Maher

   Pages 71-101

6. Animal Models of Alcoholic Liver Disease

   • Jun Xu, Hidekazu Tsukamoto

   Pages 103-119

7. Animal Models of Nonalcoholic Fatty Liver Disease

   • Mariana Luisa Verdelho Moutinho Machado, Anna Mae Diehl

   Pages 121-145

8. Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease

   • Silvia Sookoian, Carlos Jose Pirola

   Pages 147-163

9. Clinical Features, Disease Modifiers, and Natural History of Alcoholic Liver Disease

   • Luis S. Marsano, Vatsalya Vatsalya, Ammar Hassan, Craig J. McClain

   Pages 165-182

10. Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History

    • Dawn M. Torres, Stephen A. Harrison

    Pages 183-194

11. Diagnostic Approaches and Clinical End Points of Treatment in Alcoholic Liver Disease

    • Jaeyoun Cheong, Eva Stein, Ramon Bataller

    Pages 195-209

12. Diagnostic Considerations and Clinical End Points for Nonalcoholic Steatohepatitis

    • Arun J. Sanyal

    Pages 211-221

13. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease

    • Pierre Bedossa, David E. Kleiner

    Pages 223-247

14. Hepatic and Extrahepatic Malignancies in Alcoholic Liver Disease

    • Samir Zakhari, Svetlana Radaeva, Vasilis Vasiliou

    Pages 249-269

15. Hepatic and Extrahepatic Malignancies in NAFLD

    • Fabio Nascimbeni, Vlad Ratziu

    Pages 271-290

16. Treatment of Alcoholic Liver Disease Including Emerging Therapies, Novel Targets, and Liver Transplantation

    • Jan Petrasek, Gyongyi Szabo

    Pages 291-311

17. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease

    • Samer Gawrieh, Naga Chalasani

    Pages 313-337

18. Nonalcoholic Fatty Liver Disease in Children

    • Hannah I. Awai, Kimberly P. Newton, Jeffrey B. Schwimmer

    Pages 339-362

19. Back Matter

    Pages 363-372

    PDF

This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies.

Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.

• Liver histology
• Liver transplantation
• Microbiome
• NAFLD
• NASH
• hepatology

“The purpose is to serve as a review of both mechanisms of liver disease. The book is meant to compare the two unique diseases, which share several mechanisms. … The book summarizes current knowledge and contains updates on recent research. … This is a high quality resource on the topic of alcoholic and nonalcoholic fatty liver disease, providing an in-depth discussion of the mechanisms … .” (Ryan R. Sefcik, Doody's Book Reviews, June, 2016)

• Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, USA

  Naga Chalasani

• Department of Medicine, University of Massachusetts Medical School, Worcester, USA

  Gyongyi Szabo

Drs. Chalasani and Szabo are senior investigators in the field of fatty liver disease and have had extensive federal funding to investigate these areas. They both hold leadership positions and are recognized as experts in the field of fatty liver disease. For example, Dr. Chalasani is the lead author of the multi-society practice guideline on the diagnosis and management of nonalcoholic fatty liver disease& Dr. Szabo is the president-elect of the American Association for the Study of Liver Disease which is the largest liver society in the world. They are also actively practicing clinicians and thus aware of clinically relevant knowledge gaps in the field.

Policies and ethics